Effects of activation of AMPK on human breast cancer cell lines with different genetic backgrounds

Oncology Letters

Volumn 3, Issue 1, 2012, Pages 224-228

  El Masry, Omar S ^a   Brown, Barry L ^a   Dobson, Pauline R M ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Amp activated protein kinase; Breast cancer

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; ESTROGEN RECEPTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE ACTIVATOR; PHENFORMIN; PROTEIN P53;

APOPTOSIS; ARTICLE; BREAST CANCER; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; PROTEIN PHOSPHORYLATION; TREATMENT RESPONSE; TUMOR GROWTH;

EID: 84855242079     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2011.458     Document Type: Article

References (17)

1. Evans DG and Howell A: Breast cancer risk-assessment models: Breast Cancer Res 9: 213, 2007.
2. Lorincz AM and Sukumar S: Molecular links between obesity and breast cancer. Endocr Relat Cancer 13: 279-292, 2006.
3. Todorov PT, McDevitt TM, Meyer DJ, Ueyama H, Ohkubo I and Tisdale MJ: Purification and characterization of a tumor lipid-mobilizing factor. Cancer Res 58: 2353-2358, 1998.
4. Katajisto P, Vallenius T, Vaahtomeri K, Ekman N, Udd L, Tiainen M and Makela TP: The LKB1 tumor suppressor kinase in human disease. Biochim Biophys Acta 1775: 63-75, 2007.
5. Lizcano JM, Goransson O, Toth R, Deak M, Morrice NA, Boudeau J, Hawley SA, Udd L, Makela TP, Hardie DG and Alessi DR: LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1. EMBO J 23: 833-843, 2004.
6. Viollet B, Athea Y, Mounier R, Guigas B, Zarrinpashneh E, Horman S, Lantier L, Hebrard S, Devin-Leclerc J, Beauloye C, Foretz M, Andreelli F, Ventura-Clapier R and Bertrand L: AMPK: Lessons from transgenic and knockout animals. Front Biosci 14: 19-44, 2009.
7. Bode AM and Dong Z: Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer 4: 793-805, 2004.
8. Caraci F, Chisari M, Frasca G, Chiechio S, Salomone S, Pinto A, Sortino MA and Bianchi A: Effects of phenformin on the proliferation of human tumor cell lines. Life Sci 74: 643-650, 2003.
9. Luo Z, Saha AK, Xiang X and Ruderman NB: AMPK, the metabolic syndrome and cancer. Trends Pharmacol Sci 26: 69-76, 2005.
10. Xiang X, Saha AK, Wen R, Ruderman NB and Luo Z: AMP-activated protein kinase activators can inhibit the growth of prostate cancer cells by multiple mechanisms. Biochem Biophys Res Commun 321: 161-167, 2004.
11. Rattan R, Giri S, Singh AK and Singh I: 5-Aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside inhibits cancer cell proliferation in vitro and in vivo via AMP-activated protein kinase. J Biol Chem 280: 39582-39593, 2005.
12. Yang L, Cao Z, Yan H and Wood WC: Coexistence of high levels of apoptotic signaling and inhibitor of apoptosis proteins in human tumor cells: implication for cancer specific therapy. Cancer Res 63: 6815-6824, 2003.
13. Butler H and Korbonits M: Cannabinoids for clinicians: the rise and fall of the cannabinoid antagonists. Eur J Endocrinol 161: 655-662, 2009.
14. Sengupta TK, Leclerc GM, Hsieh-Kinser TT, Leclerc GJ, Singh I and Barredo JC: Cytotoxic effect of 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside (AICAR) on childhood acute lymphoblastic leukemia (ALL) cells: implication for targeted therapy. Mol Cancer 6: 46, 2007.
15. Mukherjee P, Mulrooney TJ, Marsh J, Blair D, Chiles TC and Seyfried TN: Differential effects of energy stress on AMPK phosphorylation and apoptosis in experimental brain tumor and normal brain. Mol Cancer 7: 37, 2008.
16. Elmore S: Apoptosis: a review of programmed cell death. Toxicol Pathol 35: 495-516, 2007.
17. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ and Moller DE: Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108: 1167-1174, 2001.